Anti MUC 1 chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics

Drug Profile

Anti MUC 1 chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics

Alternative Names: Anti-MUC 1 CART cell therapy; MUC-1 CAR T cell

Latest Information Update: 27 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innovative Cellular Therapeutics
  • Class CAR-T cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer; Lung cancer; Pancreatic cancer

Most Recent Events

  • 01 Dec 2017 Phase-I clinical trials in Breast cancer (Metastatic disease, Second-line therapy or greater) in China (Parenteral) (ChiCTR1800014935)
  • 01 Dec 2017 Phase-I clinical trials in Lung cancer in China (Parenteral) (ChiCTR1800014954)
  • 01 Dec 2017 Phase-I clinical trials in Pancreatic cancer in China (Parenteral) (ChiCTR1800014927)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top